![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLA2G4A |
Gene summary for PLA2G4A |
![]() |
Gene information | Species | Human | Gene symbol | PLA2G4A | Gene ID | 5321 |
Gene name | phospholipase A2 group IVA | |
Gene Alias | GURDP | |
Cytomap | 1q31.1 | |
Gene Type | protein-coding | GO ID | GO:0001516 | UniProtAcc | B4DZI4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5321 | PLA2G4A | AEH-subject1 | Human | Endometrium | AEH | 2.48e-11 | 4.12e-01 | -0.3059 |
5321 | PLA2G4A | EEC-subject3 | Human | Endometrium | EEC | 1.41e-21 | 8.17e-01 | -0.2525 |
5321 | PLA2G4A | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.12e-03 | -4.38e-02 | -0.1917 |
5321 | PLA2G4A | P9T-E | Human | Esophagus | ESCC | 1.64e-23 | 5.21e-01 | 0.1131 |
5321 | PLA2G4A | P10T-E | Human | Esophagus | ESCC | 4.71e-04 | 1.82e-02 | 0.116 |
5321 | PLA2G4A | P11T-E | Human | Esophagus | ESCC | 3.52e-06 | 3.34e-01 | 0.1426 |
5321 | PLA2G4A | P16T-E | Human | Esophagus | ESCC | 1.29e-06 | 8.82e-02 | 0.1153 |
5321 | PLA2G4A | P19T-E | Human | Esophagus | ESCC | 1.08e-07 | 4.21e-01 | 0.1662 |
5321 | PLA2G4A | P22T-E | Human | Esophagus | ESCC | 1.55e-10 | 7.76e-02 | 0.1236 |
5321 | PLA2G4A | P23T-E | Human | Esophagus | ESCC | 2.68e-05 | 2.14e-01 | 0.108 |
5321 | PLA2G4A | P26T-E | Human | Esophagus | ESCC | 6.03e-07 | 6.04e-02 | 0.1276 |
5321 | PLA2G4A | P30T-E | Human | Esophagus | ESCC | 1.97e-17 | 7.59e-01 | 0.137 |
5321 | PLA2G4A | P31T-E | Human | Esophagus | ESCC | 7.57e-20 | 4.55e-01 | 0.1251 |
5321 | PLA2G4A | P32T-E | Human | Esophagus | ESCC | 9.41e-06 | 1.09e-01 | 0.1666 |
5321 | PLA2G4A | P39T-E | Human | Esophagus | ESCC | 1.35e-02 | 1.93e-02 | 0.0894 |
5321 | PLA2G4A | P42T-E | Human | Esophagus | ESCC | 2.63e-05 | 1.93e-01 | 0.1175 |
5321 | PLA2G4A | P52T-E | Human | Esophagus | ESCC | 7.51e-05 | 1.54e-02 | 0.1555 |
5321 | PLA2G4A | P54T-E | Human | Esophagus | ESCC | 5.95e-04 | 1.22e-01 | 0.0975 |
5321 | PLA2G4A | P57T-E | Human | Esophagus | ESCC | 2.67e-02 | 8.10e-02 | 0.0926 |
5321 | PLA2G4A | P62T-E | Human | Esophagus | ESCC | 3.86e-10 | 8.21e-02 | 0.1302 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
GO:00466774 | Esophagus | ESCC | response to antibiotic | 34/8552 | 47/18723 | 1.91e-04 | 1.21e-03 | 34 |
GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
GO:00442427 | Esophagus | ESCC | cellular lipid catabolic process | 121/8552 | 214/18723 | 8.63e-04 | 4.43e-03 | 121 |
GO:000669211 | Esophagus | ESCC | prostanoid metabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
GO:000669311 | Esophagus | ESCC | prostaglandin metabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
GO:00712366 | Esophagus | ESCC | cellular response to antibiotic | 11/8552 | 14/18723 | 1.30e-02 | 4.27e-02 | 11 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0466614 | Endometrium | AEH | Fc gamma R-mediated phagocytosis | 27/1197 | 97/8465 | 3.02e-04 | 2.39e-03 | 1.75e-03 | 27 |
hsa0466615 | Endometrium | AEH | Fc gamma R-mediated phagocytosis | 27/1197 | 97/8465 | 3.02e-04 | 2.39e-03 | 1.75e-03 | 27 |
hsa0466621 | Endometrium | EEC | Fc gamma R-mediated phagocytosis | 27/1237 | 97/8465 | 5.15e-04 | 3.83e-03 | 2.85e-03 | 27 |
hsa0466631 | Endometrium | EEC | Fc gamma R-mediated phagocytosis | 27/1237 | 97/8465 | 5.15e-04 | 3.83e-03 | 2.85e-03 | 27 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLA2G4A | SNV | Missense_Mutation | novel | c.1837N>C | p.Asp613His | p.D613H | P47712 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PLA2G4A | SNV | Missense_Mutation | c.704N>T | p.Ser235Leu | p.S235L | P47712 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLA2G4A | SNV | Missense_Mutation | novel | c.424N>T | p.Pro142Ser | p.P142S | P47712 | protein_coding | tolerated(0.56) | benign(0.003) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
PLA2G4A | SNV | Missense_Mutation | c.1430N>G | p.Ala477Gly | p.A477G | P47712 | protein_coding | tolerated(0.12) | benign(0.075) | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
PLA2G4A | SNV | Missense_Mutation | c.1893G>C | p.Glu631Asp | p.E631D | P47712 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PLA2G4A | SNV | Missense_Mutation | novel | c.841N>G | p.Lys281Glu | p.K281E | P47712 | protein_coding | tolerated(0.72) | benign(0.007) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLA2G4A | SNV | Missense_Mutation | c.1118T>G | p.Phe373Cys | p.F373C | P47712 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PLA2G4A | SNV | Missense_Mutation | c.1757N>T | p.Pro586Leu | p.P586L | P47712 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A1KS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
PLA2G4A | SNV | Missense_Mutation | c.768G>T | p.Met256Ile | p.M256I | P47712 | protein_coding | tolerated(0.06) | benign(0.38) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
PLA2G4A | SNV | Missense_Mutation | c.1445G>C | p.Arg482Thr | p.R482T | P47712 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | FLUOROMETHOLONE | FLUOROMETHOLONE | ||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | FLURANDRENOLIDE | FLURANDRENOLIDE | ||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | MEDRYSONE | MEDRYSONE | ||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | FLUTICASONE PROPIONATE | |||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | FLUNISOLIDE | FLUNISOLIDE | ||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | Pyrazolones | 26398624 | ||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | propionic acid derivatives | 26398624 | ||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | diclofenac | DICLOFENAC | 26398624 | |
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | atenolol | ATENOLOL | ||
5321 | PLA2G4A | ENZYME, DRUGGABLE GENOME | FLUOCINOLONE ACETONIDE |
Page: 1 2 |